Glaxo submits Promacta sNDA; NICE denies Alimta in expanded lung cancer use; Merck KGaA ups its dividend;

@FiercePharma: Best-read FP story yesterday: Eliquis earns best safety score in its class in analysis of FDA adverse event reports. Piece | Follow @FiercePharma

@TracyStaton: J&J's high-stakes argument against a $1.2B Risperdal fine begins in Arkansas' top court. News | Follow @TracyStaton

@EricPFierce: Mylan earnings get shot in the arm from epinephrine shortage. More | Follow @EricPFierce

@CarlyHFierce: Bayer's 2013 earnings are out. Release: More. BloombergNews' take: Article | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) has submitted a supplemental New Drug Application to the FDA for anemia drug Promacta. More

> Merck KGaA will hike its dividend to €1.90 a share. Report

> The U.K.'s cost-effectiveness watchdog has shot down an expanded lung cancer indication for Eli Lilly's ($LLY) Alimta. Report

> Arena ($ARNA), maker of obesity drug Belviq, saw its fourth-quarter net losses widen to $0.11 per share. News

> The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a new tablet formulation of Merck's ($MRK) antifungal Noxafil. More

Medical Device News

@FierceMedDev: Twisted fibers make low-cost artificial muscle to be used in robotics, prosthetics. Item | Follow @FierceMedDev

@MarkHFierce: VC options may have declined in the device and Dx worlds, but they're far from gone. See: Abingworth. Story | Follow @MarkHFierce

@MichaelGFierce: A tattoo to deliver a treatment for deadly sandfly-borne skin disease? It's a first. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Only 15 percent of all ovarian cancers are detected in early stages--but nVision Medical plans to change all that. Article | Follow @EmilyWFierce

> HeartWare's heart pump revenue jumped in Q4, thanks to U.S. growth. News

> Illumina's prenatal blood test shows standout results in NEJM. More

> S. Korea is trying to decide whether the Galaxy S5 is a medical device. Story

Biotech News

@FierceBiotech: Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck. More | Follow @FierceBiotech

@JohnCFierce: Report: Novartis reorganization quietly claims 3,000 jobs in just 4 months. News | Follow @JohnCFierce

@DamianFierce: Bayer looks to boost its R&D budget to $15.5B over the next three years. News | Follow @DamianFierce

@EmilyMFierce: Brain cell communication plays role in regulating tau in Alzheimer's. Story | Follow @EmilyMFierce

> Celgene gambles $50M on Abide and its R&D work on enzyme 'superfamily'. More

> Bayer plans to ratchet up its R&D spend and chase down some deals. Article

And Finally... Novartis ($NVS), Sanofi's ($SNY) Genzyme, Alexion ($ALXN) and others have joined the global rare disease community in recognition of Friday's Rare Disease Day. More

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.